Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

Ionis reports positive phase 2b results for fesomersen in thrombosis prevention

Ionis reports positive phase 2b results for fesomersen in thrombosis prevention

2b study of fesomersen in patients with ESRD, which we believe supports continued advancement of this potential novel anti-thrombotic therapy for patients with renal and cardiovascular diseases.

Latest news

More from news
Approximately 5 fully matching, plus 104 partially matching documents found.

Latest Intelligence

  • Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease

    Cardiovascular diseases (CVD) are the leading cause of death globally, accounting for 32% of all deaths, according to WHO statistics. ... So-Young Kim is VP Head TA Thrombosis &Vascular Diseases, Clinical Development at Bayer AG.

  • The promise of precision medicine The promise of precision medicine

    Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... In Qatar, research into genomics and precision medicine is being used to tackle diseases such as obesity, diabetes and cardiovascular disease.

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    As we continue to follow the science to understand the underlying mechanisms of associated cardiovascular, renal and metabolic diseases, we are working to address shared risk factors and develop solutions designed ... Joris Silon is Senior Vice President,

  • On our best behaviour On our best behaviour

    The main disease areas of focus have understandably been chronic diseases, including obesity, diabetes, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). ... A shift in behaviour could be very beneficial for pharma. With

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Drug discovery is almost entirely focused on controlling protein activity to treat or cure diseases, using small-molecule or biologics to inhibit or in some cases boost the activity of a ... Big pharma and new start-ups. Arvinas recently attracted a $750m

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...